Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,890 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC.
Morimoto K, Sawada R, Yamada T, Azuma K, Ito K, Goto Y, Kimura H, Harada T, Shiotsu S, Tamiya N, Chihara Y, Takeda T, Hiranuma O, Hasegawa I, Morimoto Y, Iwasaku M, Tokuda S, Takayama K. Morimoto K, et al. Among authors: kimura h. JTO Clin Res Rep. 2022 Aug 6;3(9):100388. doi: 10.1016/j.jtocrr.2022.100388. eCollection 2022 Sep. JTO Clin Res Rep. 2022. PMID: 36082280 Free PMC article.
Clinical impact of amrubicin monotherapy in patients with relapsed small cell lung cancer: a multicenter retrospective study.
Uda S, Yamada T, Yoshimura A, Goto Y, Yoshimine K, Nakamura Y, Shiotsu S, Yokoi T, Tamiya N, Kimura H, Chihara Y, Umeda Y, Izumi M, Takeda T, Yamada T, Hibino M, Hiranuma O, Ito K, Okada A, Osugi S, Takemura Y, Ishii H, Chibana K, Hasegawa I, Morimoto Y, Iwasaku M, Tokuda S, Takayama K. Uda S, et al. Among authors: kimura h. Transl Lung Cancer Res. 2022 Sep;11(9):1847-1857. doi: 10.21037/tlcr-22-160. Transl Lung Cancer Res. 2022. PMID: 36248326 Free PMC article.
Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial.
Tanimura K, Uchino J, Kimura H, Hiranuma O, Chihara Y, Tanzawa S, Takumi C, Kita T, Inoue K, Minato K, Takemoto S, Nakao A, Yoshimura K, Takayama K. Tanimura K, et al. Among authors: kimura h. Oncologist. 2023 Jun 2;28(6):551-e454. doi: 10.1093/oncolo/oyad013. Oncologist. 2023. PMID: 37053467 Free PMC article. Clinical Trial.
Prophylactic treatment of dacomitinib-induced skin toxicities in epidermal growth factor receptor-mutated non-small-cell lung cancer: A multicenter, Phase II trial.
Iwasaku M, Uchino J, Chibana K, Tanzawa S, Yamada T, Tobino K, Uchida Y, Kijima T, Nakatomi K, Izumi M, Tamiya N, Kimura H, Fujita M, Honda R, Takumi C, Yamada T, Kaneko Y, Kiyomi F, Takayama K. Iwasaku M, et al. Among authors: kimura h. Cancer Med. 2023 Jul;12(14):15117-15127. doi: 10.1002/cam4.6184. Epub 2023 Jun 3. Cancer Med. 2023. PMID: 37269194 Free PMC article. Clinical Trial.
A phase 2 trial of durvalumab treatment following radiation monotherapy in patients with non-small cell lung cancer ineligible for stage III chemoradiotherapy: The SPIRAL-RT study.
Yamada T, Goto Y, Tanaka H, Kimura H, Minato K, Gyotoku H, Honda T, Watanabe S, Morimoto K, Kiyomi F, Uchino J, Takayama K. Yamada T, et al. Among authors: kimura h. Eur J Cancer. 2023 Dec;195:113373. doi: 10.1016/j.ejca.2023.113373. Epub 2023 Oct 22. Eur J Cancer. 2023. PMID: 37890349 Free article. Clinical Trial.
EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer.
Kimura H, Kasahara K, Shibata K, Sone T, Yoshimoto A, Kita T, Ichikawa Y, Waseda Y, Watanabe K, Shiarasaki H, Ishiura Y, Mizuguchi M, Nakatsumi Y, Kashii T, Kobayashi M, Kunitoh H, Tamura T, Nishio K, Fujimura M, Nakao S. Kimura H, et al. J Thorac Oncol. 2006 Mar;1(3):260-7. doi: 10.1016/s1556-0864(15)31577-x. J Thorac Oncol. 2006. PMID: 17409866 Free article. Clinical Trial.
Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma.
Kasahara K, Arao T, Sakai K, Matsumoto K, Sakai A, Kimura H, Sone T, Horiike A, Nishio M, Ohira T, Ikeda N, Yamanaka T, Saijo N, Nishio K. Kasahara K, et al. Among authors: kimura h. Clin Cancer Res. 2010 Sep 15;16(18):4616-24. doi: 10.1158/1078-0432.CCR-10-0383. Epub 2010 Aug 2. Clin Cancer Res. 2010. PMID: 20679350
Selective gene amplification to detect the T790M mutation in plasma from patients with advanced non-small cell lung cancer (NSCLC) who have developed epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance.
Nishikawa S, Kimura H, Koba H, Yoneda T, Watanabe S, Sakai T, Hara J, Sone T, Kasahara K, Nakao S. Nishikawa S, et al. Among authors: kimura h. J Thorac Dis. 2018 Mar;10(3):1431-1439. doi: 10.21037/jtd.2018.01.144. J Thorac Dis. 2018. PMID: 29707292 Free PMC article.
Long-Term Survival of Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor Monotherapy in Real-World Settings.
Yoneda T, Sone T, Koba H, Shibata K, Suzuki J, Tani M, Nishitsuji M, Nishi K, Kobayashi T, Shirasaki H, Araya T, Kita T, Kase K, Yamamura K, Terada N, Nishikawa S, Tambo Y, Kimura H, Kasahara K. Yoneda T, et al. Among authors: kimura h. Clin Lung Cancer. 2022 Sep;23(6):467-476. doi: 10.1016/j.cllc.2022.03.008. Epub 2022 May 1. Clin Lung Cancer. 2022. PMID: 35618628
Genomic evolutional analysis of surgical resected specimen to assess osimertinib as a first-line therapy in two patients with lung cancer harboring EGFR mutation: Case series.
Koba H, Yoneda T, Morita H, Kimura H, Murase Y, Terada N, Tambo Y, Horie M, Kasahara K, Matsumoto I, Yano S. Koba H, et al. Among authors: kimura h. Thorac Cancer. 2024 Mar;15(8):661-666. doi: 10.1111/1759-7714.15241. Epub 2024 Feb 7. Thorac Cancer. 2024. PMID: 38323355 Free PMC article.
5,890 results